RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01071564 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacogenomic Study
OTHER: Pharmacological Study
DRUG: Vismodegib

Sponsor

National Cancer Institute (NCI)